Comparing the Spanish Version of CANreduce With or Without Psychological Support and Treatment as Usual, Reducing Cannabis Use. (CANREDUCE)

November 5, 2021 updated by: Parc de Salut Mar

Evaluación de Una Herramienta E-Salud Para la reducción Del Consumo de Cannabis

Cannabis is the most widely used psychoactive substance around the world after alcohol and tobacco. Although approximately one in ten users develop serious problems of dependency, only a small number attend outpatient addiction counseling centers. CANreduce is an adherence-focused guidance enhanced web-based self-help program with promising results in German and other languages. It also reaches those users who hesitate to approach such treatment centers and help them to reduce their cannabis use.

This study will test the effectiveness of the Spanish version of the enhanced web-based self-help intervention with psychological support, an enhanced web-based self-help intervention (without psychological support) and a waiting list control in reducing cannabis use in problematic users.

Study Overview

Status

Recruiting

Study Type

Interventional

Enrollment (Anticipated)

300

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

  • Name: Marta Torrens, PhD
  • Phone Number: 1697 0034933160697
  • Email: mtorrens@imim.es

Study Contact Backup

  • Name: Juan-Ignacio Mestre-Pinto, PhD
  • Phone Number: 0034933160697
  • Email: jmestre@imim.es

Study Locations

    • Catalunya
      • Barcelona, Catalunya, Spain, 08003
        • Recruiting
        • Juan-Ignacio Mestre-Pinto
        • Contact:

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (ADULT, OLDER_ADULT)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Cannabis use of at least once a week 30 days prior to study entry
  • At least 18 years old
  • At least weekly internet access and a valid email address

Exclusion Criteria:

  • Participant reports current pharmacological psychiatric disease or history of psychosis, schizophrenia, bipolar type I disorder or significant current suicidal or homicidal thoughts
  • Use of other pharmacological and psychosocial treatments for cannabis use disorders
  • Inability to read or write in Spanish

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: TREATMENT
  • Allocation: RANDOMIZED
  • Interventional Model: PARALLEL
  • Masking: SINGLE

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
EXPERIMENTAL: CANreduce with psychological support
Adherence-focused guidance enhanced web-based self-help for the reduction of cannabis use with psychological support
CANreduce is an automated web-based self-help tool based on classical Cognitive Behavioral Treatment (CBT) approaches for treating cannabis dependence. It will consist of a consumption diary, eight modules designed to reduce cannabis use based on the principles of motivational interviewing, self-control practices, and methods of cognitive behavioral therapy ( strategies for goal achievement, Identifying risk situations, Dealing with cannabis craving, Dealing with relapses, Working on needs, Saying "no" to foster refusal skills, Dealing with burdens, Preserving achievements). Participants can study all modules at their own pace and order, though a specific order will be advised.
Other Names:
  • CANreduce: Adherence-focused guidance enhanced web-based self-help for the reduction of cannabis use with psychological support
psychological support
EXPERIMENTAL: CANreduce without psychological support
Adherence-focused guidance enhanced web-based self-help for the reduction of cannabis use without psychological support
CANreduce is an automated web-based self-help tool based on classical Cognitive Behavioral Treatment (CBT) approaches for treating cannabis dependence. It will consist of a consumption diary, eight modules designed to reduce cannabis use based on the principles of motivational interviewing, self-control practices, and methods of cognitive behavioral therapy ( strategies for goal achievement, Identifying risk situations, Dealing with cannabis craving, Dealing with relapses, Working on needs, Saying "no" to foster refusal skills, Dealing with burdens, Preserving achievements). Participants can study all modules at their own pace and order, though a specific order will be advised.
Other Names:
  • CANreduce: Adherence-focused guidance enhanced web-based self-help for the reduction of cannabis use with psychological support
NO_INTERVENTION: Treatment as usual
Users will be prompt to a web with a list of the treatment centers nearby their postal code

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change in the number of days of self-reported cannabis use in the past 30 days (TLFB)
Time Frame: Baseline, 6, 12 and 24 weeks.

Participants enter their cannabis consumption frequency into their consumption diary every week.

More days of self-reported cannabis use indicate worse state

Baseline, 6, 12 and 24 weeks.

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change in the number of days of weekly self-reported cannabis use Time Life Follow Back (TLFB)
Time Frame: Baseline, 6, 12 and 24 weeks.

Participants enter their cannabis consumption frequency into their consumption diary every week.

More days of self-reported cannabis use indicate a worse outcome

Baseline, 6, 12 and 24 weeks.
Change in the quantity of weekly standard joints (TLFB with predifined cannabis standard joints)
Time Frame: Baseline, 6, 12 and 24 weeks.

Participants enter their cannabis consumption quantity into their consumption diary every week.

More number of weekly standard joints indicate a worse outcome

Baseline, 6, 12 and 24 weeks.
Change in the scoring of the Cannabis Use Disorder Identification Test - Revised (CUDIT-R)
Time Frame: Baseline, 6, 12 and 24 weeks.

CUDIT-R was developed containing 8 items, two each from the domains of consumption, cannabis problems (abuse), dependence, and psychological features. It has excellent psychometric properties. High sensitivity (91%) and specificity (90%).

This questionnaire was designed for self administration and is scored by adding each of the 8 items:

  • Question 1-7 are scored on a 0-4 scale (range 0-28)
  • Question 8 is scored 0, 2 or 4.
  • Score range 0-32 Scores of 8 or more indicate hazardous cannabis use, while scores of 12 or more indicate a possible cannabis use disorder for which further intervention may be required.

Higher scores indicate a worse outcome

Baseline, 6, 12 and 24 weeks.
Change in the scoring of the Severity Dependence Scale (SDS)
Time Frame: Baseline, 6, 12 and 24 weeks.
SDS is a standard instrument to assess the severity to any drug dependence. Each of the five items is scored on a 4-point scale (0-3). The total score is obtained through the addition of the 5-item ratings (0-15). The higher the score the higher the level of dependence.
Baseline, 6, 12 and 24 weeks.
Change in the scoring of the Alcohol Use Disorders Identification Test (AUDIT)
Time Frame: Baseline, 6, 12 and 24 weeks.
AUDIT is a 10-item screening tool developed by the World Health Organization (WHO) to assess alcohol consumption, drinking behaviors, and alcohol-related problems. Each item scores 0-4, The total score ranges from 0-40. A score of 8 or more is considered to indicate hazardous or harmful alcohol use. The AUDIT has been validated across genders and in a wide range of racial/ethnic groups and is well suited for use in primary care settings. Higher scores indicate a worse outcome
Baseline, 6, 12 and 24 weeks.
Change in the scoring of the PROMIS Emotional Distress - Depression - Short Form 8b
Time Frame: Baseline, 6, 12 and 24 weeks.

PROMIS (Patient-Reported Outcomes Measurement Information System) is a set of person-centered measures that evaluates and monitors physical, mental, and social health in adults and children. It can be used with the general population and with individuals living with chronic conditions. Developed and validated with state-of-the-science methods to be psychometrically sound and to transform how life domains are measured.

8 items 1-5, score ranges 8-40 Higher scores indicate a worse outcome

Baseline, 6, 12 and 24 weeks.
Change in the scoring of the PROMIS Anxiety 8a - Adult v1.0
Time Frame: Baseline, 6, 12 and 24 weeks.

PROMIS (Patient-Reported Outcomes Measurement Information System) is a set of person-centered measures that evaluates and monitors physical, mental, and social health in adults and children. It can be used with the general population and with individuals living with chronic conditions. Developed and validated with state-of-the-science methods to be psychometrically sound and to transform how life domains are measured.

8 items 1-5, score ranges 8-40 Higher scores indicate a worse outcome

Baseline, 6, 12 and 24 weeks.
Change in the scoring of the EQ-5D-5L
Time Frame: Baseline, 6, 12 and 24 weeks.

EQ-5D-5L is a self-assessed, health related, quality of life questionnaire. The scale measures quality of life on a 5-component scale including mobility, self-care, usual activities, pain/discomfort, and anxiety/depression.

Score ranges from less than 0 (where 0 is the value of a health state equivalent to dead; negative values representing values as worse than dead) to 1 (the value of full health),

The second part of the questionnaire consists of a visual analogue scale (VAS) on which the patient rates his/her perceived health from 0 (the worst imaginable health) to 100 (the best imaginable health).

Baseline, 6, 12 and 24 weeks.

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Marta Torrens, PhD, Hospital del Mar Research Institute (IMIM)

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (ACTUAL)

November 10, 2020

Primary Completion (ANTICIPATED)

November 1, 2022

Study Completion (ANTICIPATED)

December 1, 2022

Study Registration Dates

First Submitted

August 12, 2020

First Submitted That Met QC Criteria

August 14, 2020

First Posted (ACTUAL)

August 18, 2020

Study Record Updates

Last Update Posted (ACTUAL)

November 8, 2021

Last Update Submitted That Met QC Criteria

November 5, 2021

Last Verified

November 1, 2021

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Cannabis Use Disorder

Subscribe